Design Therapeutics Inc (DSGN) Stock Price, Quote & News

Latest News on DSGN

Mar 10, 2025, 7:07 AM EDT - 25 days ago

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 4 weeks ago

Design Therapeutics to Participate in Leerink's Global Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 5 months ago

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Nov 7, 2024, 4:01 PM EST - 5 months ago

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Aug 5, 2024, 8:00 AM EDT - 8 months ago

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

May 8, 2024, 4:05 PM EDT - 11 months ago

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

May 7, 2024, 6:30 AM EDT - 11 months ago

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Mar 19, 2024, 8:44 PM EDT - 1 year ago

Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:01 PM EDT - 1 year ago

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Mar 12, 2024, 6:30 AM EDT - 1 year ago

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Nov 13, 2023, 4:05 PM EST - 1 year ago

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

Aug 15, 2023, 8:17 AM EDT - 1 year ago

Design Therapeutics stock plunges on trial results for neuromuscular disease treatment

Aug 14, 2023, 4:05 PM EDT - 1 year ago

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

Aug 14, 2023, 4:01 PM EDT - 1 year ago

Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

May 31, 2023, 6:30 AM EDT - 2 years ago

Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

May 9, 2023, 4:05 PM EDT - 2 years ago

Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results

Apr 24, 2023, 6:30 AM EDT - 2 years ago

Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023

Mar 14, 2023, 4:05 PM EDT - 2 years ago

Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 8, 2023, 6:30 AM EST - 2 years ago

Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

Dec 7, 2022, 4:01 PM EST - 2 years ago

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

Nov 3, 2022, 4:05 PM EDT - 2 years ago

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

Oct 17, 2022, 4:05 PM EDT - 2 years ago

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

Sep 22, 2022, 6:30 AM EDT - 2 years ago

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

Aug 8, 2022, 4:05 PM EDT - 2 years ago

Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

Aug 3, 2022, 6:30 AM EDT - 2 years ago

Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

Jun 1, 2022, 6:30 AM EDT - 3 years ago

Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

May 9, 2022, 4:05 PM EDT - 3 years ago

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

Mar 30, 2022, 6:30 AM EDT - 3 years ago

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia

Mar 10, 2022, 4:02 PM EST - 3 years ago

Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

Mar 9, 2022, 6:30 AM EST - 3 years ago

Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022

Feb 28, 2022, 4:05 PM EST - 3 years ago

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia

Feb 10, 2022, 6:30 AM EST - 3 years ago

Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Feb 1, 2022, 4:05 PM EST - 3 years ago

Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer

Jan 19, 2022, 12:51 PM EST - 3 years ago

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Nov 9, 2021, 4:05 PM EST - 3 years ago

Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results

Sep 8, 2021, 6:30 AM EDT - 3 years ago

Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1

Aug 9, 2021, 4:05 PM EDT - 3 years ago

Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results

Jun 7, 2021, 4:10 PM EDT - 4 years ago

Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

Jun 7, 2021, 4:05 PM EDT - 4 years ago

Design Therapeutics Expands Board of Directors with Key Appointments

May 10, 2021, 4:05 PM EDT - 4 years ago

Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results

Mar 30, 2021, 4:05 PM EDT - 4 years ago

Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Mar 25, 2021, 11:56 PM EDT - 4 years ago

Design Therapeutics Announces Pricing of Initial Public Offering

Mar 24, 2021, 9:00 AM EDT - 4 years ago

Design Therapeutics Seeks $228 Million In U.S. IPO

Mar 22, 2021, 6:26 AM EDT - 4 years ago

Market Cap	215.13M
Revenue (ttm)	0.00
Net Income (ttm)	-49.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	64,542
Avg Vol	139,296
Day's Range	N/A - N/A
Shares Out	56.76M
Stochastic %K	8%
Beta	1.82
Analysts	Sell
Price Target	$7.33